Cooperative Agreement U01CA086389

This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $692,491 in funding to the University of Chicago to investigate early epigenetic signatures for common cancers. The primary goals are to: 1) Train and validate individual detection models for prostate, lung, colorectal, and ovarian cancers using samples from the PLCO Cancer Screening Trial; 2) Develop a multi-cancer detection algorithm to...

The Virginia Advancing Cancer Control Equity Research Through Transformative Solutions (VA-ACCERT) Center is a cooperative agreement awarded by the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research program (CFDA 93.393). The VA-ACCERT Center is a five-year, $3,790,188 academic-public partnership that aims to improve the dissemination and implementation of health promotion and cancer prevention services within income-based communities and public housing...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $821,797 to Early IS Good, Inc. to execute a clinical validation study for their bladder cancer diagnostic assay, BCDX. BCDX is a multi-omic, multiplex diagnostic test that uses advanced nanotechnology to detect twelve different biomarkers directly from a urine sample. Feasibility studies have demonstrated the test's high sensitivity and ability...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $159,574 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to increase access and participation to early phase clinical trials for underrepresented populations, including veterans. The project aims to develop sustainable strategies to extend access and boost participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) early phase trials for...

The National Cancer Institute (NCI) awarded a $872,878 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of California, Davis (UC Davis) to lead the Latin America Genomics of Breast Cancer Risk Study (LAGENO-BCR). The goal is to study the genetic architecture of breast cancer risk in Hispanic/Latina populations and develop improved risk prediction models that account for ancestry and geographic diversity. The research will involve conducting genome-wide...

The National Cancer Institute (NCI) awarded a $686,993 Cooperative Agreement to The Trustees of Columbia University in the City of New York under the Cancer Cause and Prevention Research (CFDA 93.393) program. The 2-year project, titled "ELECTRONIC HEALTH RECORD (EHR)-BASED IMPLEMENTATION STRATEGIES AND DECISION SUPPORT FOR HEREDITARY BREAST AND OVARIAN CANCER (HBOC) GENETIC TESTING AMONG MULTIETHNIC WOMEN (ELISABETH)", seeks to address the significant underutilization of HBOC...

The National Cancer Institute (NCI) awarded a $860,545 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Miami to implement and evaluate a Comprehensive Survivorship Care (CSC) intervention in 14 Federally Qualified Health Centers (FQHCs) in South Florida. The project aims to train primary care clinicians in the CSC intervention, which integrates survivorship care plans and guidelines into the electronic medical record to improve...

This $2,078,214 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting Precision Epigenomics Inc., a University of Arizona spin-out company, to conduct a multi-site clinical validation study for their Sentinel-MPE liquid biopsy assay. The aim is to establish the diagnostic value of this assay to identify cancer in pleural effusions and validate its use for cancer detection, with the long-term goal of...

This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to further validate and refine a mass spectrometry-based proteomic assay for the early detection of pancreatic ductal adenocarcinoma (PDAC). The $585,458 award to Baylor College of Medicine will: Determine the performance characteristics and robustness of the assay for clinical utilization; 2) Refine the assay's accuracy and thresholds for...

This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $639,780 in funding to The Leland Stanford Junior University over the period of Sep 1, 2024 to Aug 31, 2029. The project aims to (1) characterize the early-stage colorectal cancer cell-free DNA (cfDNA) methylome landscape, and (2) develop a machine learning classification model for early detection of colorectal cancer using cfDNA methylation patterns. The...